Menu

CancerQlu: Kits for Testing Increased Predisposition Cancer

Detecting cancer early improves the odds of survival and limits unnecessary suffering and expense. Identification at a more easily treatable stage, versus later stages, is absolutely critical.

Your personalised CancerQlu report will provide you with the opportunity to determine an increased predisposition for a number of cancers which are associated with genetic mutations.

With cancer being one of the leading causes of death in England, knowing if an individual is at increased risk is critical. Knowing that a mutation is present, allows an individual to work with their healthcare provider, to create a personalised screening plan, which increases the chance of early detection.

Get your personalised report results

£350

Qty
SWAB Once your test arrives in the mail, use the kit to take a simple swab sample
SEND Post your sample back to our accredited labs for analysis
SUMMARY We'll provide you a detailed actionable summary of your personal results

CancerQlu is a simple saliva-based DNA test that provides individuals with the genetic information to determine whether or not they have an increased predisposition for a number of hereditary cancers associated with genetic mutations.

This DNA test is ideal for those with a family history of cancer and individuals wanting to know if they carry any of the predisposed markers for cancers such as prostate, ovarian, stomach or pancreatic. CancerQlu will help you determine if you carry BRCA1 and BRCA2 gene mutations, which are strong risk indicators for breast and ovarian cancer.

With cancer being one of the leading causes of death in England, knowing if an individual is at increased risk is critical. Knowing that a mutation is present, allows an individual to work with their health care provider, to create a personalised screening plan, which increases the chance of early detection.

Your CancerQlu custom DNA report will give you valuable genetic insights around the following core categories:

  • Male BreastXRCC2, TP53, STK11, RINT1, RAD51C, RAD50, PALB2, PTEN, NBN, MUTYH, MRE11ABRCA1, BRCA2, BRIP1, BARD1
  • ProstateATM, BRCA1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D.
  • ColorectalAPC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4.
  • StomachAPC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4.
  • PancreaticAPC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11.
  • Female BreastATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MRE11A, MUTYH, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, RINT1, STK11, TP53, XRCC2.
  • Lobular breastCDH1
  • OvarianBARD1, BRCA1, BRCA2, BRIP1, MRE11A, NBN, RAD50, RAD51C, RAD51D.
  • UterineEPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN.
  • MelanomaBRCA2, CDKN2A
  • Other cancersFH, FCLN, SDHB, VHL

When an individual tests positive for a variant of concern, the CancerQlu report provides a suggested screening protocol and provides recommendations as to which other family members should be screened for the same genetic variants of concern.

Your personalised report results are delivered in 4 to 6 weeks

Ongoing Support

The Qlu experience doesn’t end after your purchase. Whether you have a simple question or want extended support, our highly trained clinical support staff are here for you.

Still have questions?

Keep up-to-date with our latest news